Phillips 66 Laying Off Staff At Refineries, Terminals, Office

-Reuters

-Reuters

Total
0
Shares
Related Posts
Read More

Sarepta Therapeutics Reports Preliminary Q4 Net Product Revenue For ELEVIDYS Are Expected To Be ~$131.3M And $200.4M For FY23; Preliminary Total Net Product Revenue Is Expected To Total $1.145B For FY23

– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023– Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for

SRPT